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OBJECTIVE — Progressive-celllosscausescatabolismincysticﬁbrosis.Existingdiagnostic
criteria for diabetes were based on microvascular complications rather than on cystic ﬁbrosis–
speciﬁc outcomes. We aimed to relate glycemic status in cystic ﬁbrosis to weight and lung
function changes.
RESEARCH DESIGN AND METHODS — We determined peak blood glucose (BGmax)
during oral glucose tolerance tests (OGTTs) with samples every 30 min for 33 consecutive
children (aged 10.2–18 years). Twenty-ﬁve also agreed to undergo continuous glucose moni-
toring (CGM) (Medtronic). Outcome measures were change in weight standard deviation score
(wtSDS), percent forced expiratory volume in 1 s (%FEV1), and percent forced vital capacity
(%FVC) in the year preceding the OGTT.
RESULTS — DecliningwtSDSand%FVCwereassociatedwithhigherBGmax(bothP0.02)
andwithCGMtime7.8mmol/l(P0.006andP0.02,respectively)butnotwithBG120 min.
Adeclinein%FEV1wasrelatedtoCGMtime7.8mmol/l(P0.02).Usingreceiveroperating
characteristic (ROC) analysis to determine optimal glycemic cutoffs, CGM time above 7.8
mmol/l 4.5% detected declining wtSDS with 89% sensitivity and 86% speciﬁcity (area under
the ROC curve 0.89, P  0.003). BGmax 8.2 mmol/l gave 87% sensitivity and 70% speciﬁcity
(0.76, P  0.02). BG120 min did not detect declining wtSDS (0.59, P  0.41). After exclusion of
two patients with BG120 min 11.1 mmol/l, the decline in wtSDS was worse if BGmax was 8.2
mmol/l (0.3  0.4 vs. 0.0  0.4 for BGmax 8.2 mmol/l, P  0.04) or if CGM time above 7.8
mmol/l was 4.5% (0.3  0.4 vs. 0.1  0.2 for time 4.5%, P  0.01).
CONCLUSIONS —B G max 8.2 mmol/l on an OGTT and CGM time above 7.8 mmol/l
4.5% are associated with declining wtSDS and lung function in the preceding 12 months.
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P
rogressive -cell loss causes catabo-
lism and weight loss in cystic ﬁbro-
sis (1,2). Weight is a prognostic
indicator (3), and prevention of weight
decline is a major clinical objective in
children and adolescents with cystic ﬁ-
brosis. Median life expectancy of patients
withcysticﬁbrosishasrisenprogressively
over recent decades but remains drasti-
cally shorter (36 years) than that of the
general population (4). The presence of
cystic ﬁbrosis–related diabetes (CFRD) is
associated with an increase in early mor-
tality of up to sixfold (5). CFRD is usually
diagnosed by the North American Cystic
Fibrosis Foundation criteria (6) or World
Health Organization (WHO) criteria for
diabetes (7). These criteria were designed
to identify patients at risk of microvascu-
lar complications in type 2 diabetes (8)
and were not designed with cystic ﬁbro-
sis–speciﬁc outcomes in mind. Microvas-
cular complications occur in cystic
ﬁbrosis (9); however, catabolic decline in
weight and deteriorating lung function
may be more relevant outcomes. Poor
weight gain is associated with worsening
lung function (10,11), and both are asso-
ciated with early mortality (12,13).
Weight and lung function declines have
been shown to precede the diagnosis of
CFRD by standard criteria (2), but the
earliest glycemic abnormality associated
with clinical decline has not been deter-
mined.Glycemicstatuscanbeassessedin
detail using an oral glucose tolerance test
(OGTT) with 30-min samples and, more
recently, continuous interstitial ﬂuid glu-
cose monitoring (CGM). We aimed to de-
termine the relationship between
glycemic status and the change in weight
standard deviation score (wtSDS) and the
change in lung function over the preced-
ing year.
RESEARCH DESIGN AND
METHODS— In a prospective proto-
col, 33 consecutive children with cystic
ﬁbrosis (median age 13.1 years, range
10.2–18 years) underwent an OGTT
whenclinicallystablewithrespecttolung
disease, as part of an annual screening
program for all patients with cystic ﬁbro-
sis aged 10 years. All were under the
careofapediatricrespiratoryphysicianat
the Sydney Children’s Hospital cystic ﬁ-
brosis clinic. For the OGTT, patients
fasted for at least 8 h and then consumed
1.75g/kgofcarbonateddextrosesolution
(maximum 75 g). No patient refused the
OGTT. Venous or ﬁngerprick samples
were collected at 0, 30, 60, 90, and 120
min for measurement of glucose and insu-
lin. Glucose levels were determined by the
hospital laboratory, using a standard glu-
cose oxidase method (Beckman Coulter,
Fullerton, CA). Insulin levels were deter-
mined with a standard chemiluminescence
immunoassay (Immulite, limit of detection
2 mU/l; Siemens Healthcare Diagnostics,
Deerﬁeld, IL). -Cell function and insulin
sensitivity were estimated using homeosta-
sis model assessment (HOMA2) (14).
Twenty-ﬁve patients (76%) also
agreed to CGM (Medtronic). Patients re-
fusingCGMwerenotdifferentfromthose
undergoing CGM according to the clini-
cal characteristics listed in Table 1. Local
anesthetic cream and play therapy were
used to minimize the distress of intrave-
nous cannulation and insertion of the
CGM device. Mean  SD duration of
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capillary blood glucose values into the
CGM device at 60 min after CGM inser-
tion and subsequently before breakfast
and dinner each day. These premeal cali-
bration times were selected to avoid mo-
ments of rapid changes in interstitial and
blood glucose levels (J. Mastrototaro,
Medtronic, personal communication).
Percentage of time 7.8 mmol/l and area
7.8 mmol/l (millimoles per liter per
day) were determined using MiniMed So-
lutions software (MMT-7310 version
3.0C [3.0.128]; Medtronic). The 7.8
mmol/l threshold corresponds to the
WHO cutoff for impaired glucose toler-
ance (IGT) at 120 min on an OGTT.
Patients were instructed to continue
their high-energy, high-fat, cystic ﬁbro-
sis–speciﬁc diet and routine activities. No
patientsweretreatedwithglucocorticoids
at the time of the OGTT or during CGM.
Height, weight, and lung function
were measured by respiratory laboratory
staff at each visit, using a stadiometer,
electronic weight scales, and a Sensor-
Medics Vmax system (Cardinal Health,
Dublin, OH). Percent predicted forced
expiratory volume in 1 s (%FEV1) and
percent predicted forced vital capacity
(%FVC) were calculated using the
method reported by Knudson et al. (15).
wtSDS was calculated using Centers
for Disease Control and Prevention 2000
growth data with Growth Analyser Soft-
ware (version 3.5, www.growthanalyser.
org). For each patient, the rate of change
in%FEV1,%FVC,andwtSDSoverthe12
monthsbeforetheOGTTwasdetermined
from the slope obtained by linear regres-
sion analysis. The number of data points
during the 12-month period was 10  8.
The study was approved by the local
ethics committee. Statistical analysis was
performed with SPSS software (version
17).
RESULTS— According to the blood
glucose values at 0 and 120 min
(BG120 min) on the OGTT, 18 patients
(55%) had normal glucose tolerance
(NGT) by WHO criteria, 13 (39%) had
IGT (BG120 min 7.8–11 mmol/l), and 2
(6%) were diabetic (CFRD) (BG120 min
11.1 mmol/l). None had fasting hyper-
glycemia (7 mmol/l).
Figure 1 shows the time course of
blood glucose and insulin levels during
the OGTT. The peak blood glucose (BG-
max) occurred at 30 min in 6 patients
(18%), at 60 min in 15 patients (45%), at
90 min in 11 patients (33%), and at 120
min in only 1 patient (3%). In contrast
withpeakbloodglucose,peakinsulinwas
delayed. The time of peak insulin oc-
curredat120minin14of27(42%),at90
min in 8 of 27 (24%), at 60 min in 5 of 27
(15%), and at 0 or 30 min in no patients
(insulin values were incomplete or not
performed in the remaining 6 of 33 pa-
tients). Time to insulin peak was 58  19
min for those with NGT vs. 75  16 min
for those with IGT (P  0.03). Median
fasting insulin was only 4 mU/l (range
0–21 mU/l). Using HOMA2, mean -cell
function for the whole group was only
29.5% (95% CI 24.6–34.5), and median
insulin sensitivity was 90.1% (interquar-
tile range 30–417%).
Table 1 outlines the clinical charac-
teristics of the 33 patients at the time of
the OGTT. Mean wtSDS for the 33 pa-
tientswas0.78(95%CI1.2to0.4).
A decline in wtSDS over the preceding
year occurred in 23 of 33 patients (70%).
A decline in wtSDS over the preced-
ingyearwasassociatedwithhigherBGmax
(R
2  0.17, P  0.02) (Fig. 2) and longer
percentage of CGM time above 7.8
mmol/l (R
2  0.28, P  0.006) (Fig. 2),
but not with BG120 min (R
2  0.000025,
P  0.98). A decline in %FEV1 was asso-
ciated with a longer percentage of CGM
time above 7.8 mmol/l (R
2  0.16, P 
0.05),butnotwithBGmax(R
20.12,P
0.06) or BG120 min (R
2  0.0036, P 
0.75). A decline in %FVC was associated
with higher BGmax (R
2  0.16, P  0.02)
and percentage of CGM time above 7.8
mmol/l (R
2  0.20, P  0.02) but not
with BG120 min (R
2  0.032, P  0.30).
We used receiver operating charac-
teristic (ROC) analysis (16) to determine
optimal glycemic cutoffs for detecting
cystic ﬁbrosis–speciﬁc outcomes. Figure
3 shows the results of the ROC analyses
for declining wtSDS:
● CGM time above 7.8 mmol/l 4.5%
detected declining wtSDS with 89%
sensitivityand86%speciﬁcity(areaun-
der the ROC curve [AUC] 0.89, P 
0.003).
● CGM time above 7.8 mmol/l was
4.5% in 17 of 25 patients (68%).
● BGmax 8.2 mmol/l gave 87% sensitiv-
ity and 70% speciﬁcity (AUC 0.76, P 
0.02).
● BGmax was 8.2 mmol/l in 23 of 33
patients (69.7%).
● In contrast with BGmax,B G 120 min did
not detect declining wtSDS (AUC 0.59
[95% CI 0.38–0.80] P  0.41) and
BG120 min 11.1 mmol/l had only 10%
sensitivity.
Percentage of CGM time above 7.8
mmol/l was not signiﬁcantly better at de-
tecting declining wtSDS than BGmax be-
Figure1—GlucoseandinsulinlevelsduringtheOGTT.Boxesshowthemedianandinterquartile
range. Whiskers show the 5th and 95th percentiles.
Table 1—Characteristics of patients with
cystic ﬁbrosis at the time of OGTT and
change over the preceding 12 months in
weight, height, and lung function
Age (years) 13.7  2.8
Sex (male/female) 16 (49)/17 (51)
Exocrine enzyme
replacement 30 (91)
Genotype
Homozygous F508del 20 (61)
Heterozygous F508del 8 (24)
Other 3 (9)
Unknown 2 (6)
Age of diagnosis of cystic
ﬁbrosis (years) 0.47  2.0
wtSDS 0.78  1.1
Height SDS 0.41  0.92
Change in wtSDS* 0.16  0.38
Change in height SDS* 0.03  0.24
%FEV1 85  20
%FVC 94  17
Change in %FEV1* 5  8
Change in %FVC* 3  8
Data are n (%) or means  1 SD. n  33. *Over the
preceding year.
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the ROC analyses overlapped (0.5–1 and
0.56–0.96, respectively). A longer per-
centage of CGM time above 7.8 mmol/l
correlated with higher BGmax on the
OGTT (P  0.006 and R
2  0.28).
By using ROC analysis to examine
lung function, CGM time above 7.8
mmol/l 4.5% detected a fall in %FVC of
3% over the preceding 12 months (a
clinically signiﬁcant decline) (17) with
79%sensitivityand46%speciﬁcity(AUC
0.79, P  0.01), but BGmax did not (AUC
0.69, P  0.07). Neither percentage of
CGM time above 7.8 mmol/l nor OGTT
BGmax detected a fall in %FEV1 over the
preceding year of 3% (respectively,
AUC 0.65, P  0.20 and AUC 0.58, P 
0.44).BG120 minwasunabletodetectafall
3% in either %FVC (AUC 0.69, P 
0.06) or %FEV1 (AUC 0.55, P  0.64).
ROC analyses for declining weight and
lung function using percentage of CGM
time above 8.2 mmol/l and CGM area
above 8.2 mmol/l and CGM area above
7.8 mmol/l did not improve the ROC
AUC (data not shown).
Fasting insulin (but not -cell func-
tion or insulin sensitivity as measured by
HOMA2) was higher in patients with
BGmax8.2 mmol/l (6.5 mU/l, range 3–9
mU/l) than in those with BGmax 8.2
mmol/l (3 mU/l, range 0–21 mU/l, P 
0.02). WHO groups of NGT or IGT had
indistinguishable fasting insulin, -cell
function, and insulin sensitivity (data not
shown).
After the two patients with CFRD by
WHO criteria were excluded (because
they had BG120 min 11.1 mmol/l and
would currently be eligible for insulin
treatment), we compared groups deﬁned
with cut points from the ROC analysis
(Table 2). The decline in wtSDS was sig-
niﬁcantly worse in patients with BGmax
8.2 mmol/l (0.3  0.4) than in those
with BGmax 8.2 mmol/l (0.0  0.4, P 
0.04). The decline in wtSDS was also
worse in those with CGM time above 7.8
mmol/l4.5%(0.30.4vs.0.10.2
in those 4.5%, P  0.01). There was,
however, no signiﬁcant difference in
wtSDS comparing NGT (BG120 min 7.8
mmol/l) and IGT (BG120 min 7.8–11
mmol/l) groups deﬁned by WHO criteria
(0.20.4vs.0.20.4,P0.94).
Groups deﬁned by glycemic thresh-
olds(OGTTBGmax8.2or8.2mmol/l,
CGM time above 7.8 mmol/l 4.5 or
4.5%) and markers of catabolic decline
(change in wtSDS 0o r0 or change in
%FEV1 or %FVC 3o r3) were indis-
tinguishable by sex, genotype category
(F508del homozygous, F508del het-
erozygous, other, or unknown), or the
presence or absence of exocrine pancre-
atic sufﬁciency (data not shown).
CONCLUSIONS — We found that
glucose abnormalities are related to the
Figure 2—Decline in wtSDS over the preceding year by BGmax on an OGTT (A) and by percent-
ageofCGMtimeabove7.8mmol/l(B).Theverticallinesat8.2mmol/land4.5%CGMtimeabove
7.8 mmol/l represent optimal cutoffs determined by the ROC analysis in Fig. 3.
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clineinlungfunctionandweightoverthe
preceding year. Current WHO glycemic
categories of NGT and IGT (based on
BG120 minduringOGTT)couldnotdistin-
guish patients with declining wtSDS from
those with stable or increasing scores. In
contrast, we found that peak blood glu-
cose 8.2 mmol/l on 30-min sampling in
the OGTT and CGM time above 7.8
mmol/l 4.5% could do so reliably.
In a retrospective analysis of 38 dia-
betic children and adults with cystic ﬁ-
brosis and nondiabetic cystic ﬁbrosis
control subjects, Lanng et al. (2) reported
agradualdeclineinweight,BMI,andlung
function up to 4 years preceding the di-
agnosis of CFRD. Lanng et al. diagnosed
CFRD by 1985 WHO criteria (based on
BG120 min during an OGTT, but with
higher thresholds than in current use).
OurﬁndingssuggestthatBG120 mineleva-
tion is a late event, whereas peak blood
glucose 8.2 mmol/l on 30-min sam-
Figure 3—Determination of optimal glycemic cut points for detecting
declineinwtSDSoverthepreceding12monthsbyROCanalysis.A:Plot
of sensitivity vs. false-positive rate (1  speciﬁcity) for all possible cut
points in BGmax by OGTT. The point closest to the top left-hand corner
(8.2mmol/l)maximizessensitivityandspeciﬁcityandistheoptimalcut
point.B:PercentageofCGMtimeabove7.8mmol/lwiththeoptimalcut
pointof4.5%.C:SamedataforBG120 minonOGTT,whichdidnotdetect
declining wtSDS. The cut point of 11.1 mmol/l used in the WHO diag-
nostic criteria is marked.
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7.8 mmol/l 4.5% are early glucose ab-
normalities that are associated with de-
clineinlungfunctionandweightoverthe
preceding year. The patients of Lanng et
al. had lung function decline of greater
magnitude than those in our patients,
probably reﬂecting improved outcomes
over recent decades.
The central problem leading to CFRD
is insulin deﬁciency (1,18). Relative insu-
lin resistance due to stress hormones may
occur during exacerbations of lung dis-
ease, leading to temporary worsening of
glycemic status (18,19). We avoided this
confounding effect by ensuring that the
OGTT and CGM were performed when
the patients were clinically stable. Fur-
thermore, fasting insulin levels and
HOMA2 calculations of -cell function
and insulin sensitivity in our patients
demonstrated insulin deﬁciency (rather
than insulin resistance) as the underlying
problem. This result conﬁrms the ﬁnd-
ings of Mohan et al. (20), who found ab-
normalities of insulin secretion and not
insulin resistance among 60 adult pa-
tients with cystic ﬁbrosis. We found that
glucose abnormalities (on the OGTT and
CGM)andmarkersofclinicaldecline(fall
in wtSDS or lung function over the pre-
ceding year) were common and were not
limited to those with the more severe ge-
notype with homozygous F508del or to
those with exocrine insufﬁciency.
Screening practices vary, and many
centers have yet to adopt the recommen-
dation (21,22) to perform yearly OGTTs
for all patients aged 10 years. Moran et
al. (23) do perform annual OGTTs and
havereportedimprovementsinmortality,
nutritional status, and lung function in
patients with CFRD, attributing these im-
provementstoearlydiagnosisandaggres-
sive treatment.
We found that peak blood glucose is
missed in the vast majority of patients by
0- and 120-min samples (32 of 33, 97%),
indicating the need for sampling every 30
min during the OGTT. This conclusion is
supportedbytheﬁndingsofDobsonetal.
(24), who showed that nondiabetic pa-
tients with cystic ﬁbrosis had substantial
hyperglycemia at 30, 60, and 90 min, but
identical 0 and 120 min blood glucose
values compared with those of healthy
aged-matched control subjects. Hyper-
glycemia promotes bacterial growth, and
itispossiblethatthismaycontributetothe
clinical decline seen even in those with rel-
atively preserved -cell function. Palerm
(25) recently reported blood glucose values
in normal subjects after meals and found
that they rarely exceeded 150 mg/dl (8.3
mmol/l).Thisresultisverysimilartoour
cystic ﬁbrosis–speciﬁc cutoff of 8.2
mmol/l for BGmax on an OGTT.
Lippeetal.(26)reportedreducedand
delayed insulin secretion in subjects with
cystic ﬁbrosis compared with that in
healthyage-matchedcontrolsubjects.We
also found delayed peak insulin secretion
in our subjects. This ﬁnding is consistent
with a model of progressive -cell loss
leading to progressive insulin deﬁciency
and worsening glycemic status. We pro-
pose that stages of progressive cystic ﬁ-
brosis insulin deﬁciency (CFID) can be
usefully deﬁned by blood glucose on an
OGTT, as CFID1 (BGmax 8.2 and
11.1 mmol/l), CFID2 (BGmax 11.1
mmol/l and BG120 min 11.1 mmol/l),
CFID3 (BG120 min 11.1 mmol/l, corre-
sponding to CFRD without fasting hyper-
glycemia) (6), and CFID4 (fasting blood
glucose7, corresponding to CFRD with
fasting hyperglycemia). Moran et al. (27)
recently showed in a randomized con-
trolled trial that insulin treatment in
adults with CFRD without fasting hyper-
glycemia (corresponding to CFID3) re-
sulted in improved BMI, although there
wasnosigniﬁcantchangeinlungfunction
or number of hospitalizations.
We found that CGM is a useful tool
for detecting early glycemic abnormali-
ties,whichperformedaswellasOGTTon
ROC analysis and correlated with peak
blood glucose on an OGTT. It has been
used previously in cystic ﬁbrosis (24,28)
butisnotcurrentlylicensedfordiagnostic
use.Furthermore,24%ofourpatientsre-
fused to undergo CGM, whereas all
agreed to have the OGTT. It is possible
that the acceptability of CGM may im-
prove as the devices become smaller.
Our ﬁndings suggest that CFRD with
and without fasting hyperglycemia is a
late event, which is preceded by more
subtle glycemic abnormalities on CGM
and 30-min sampled OGTT. These early
glucose abnormalities are associated with
adeclineinlungfunctionandweightover
the preceding year. It is likely that pro-
gressive deﬁciency of insulin, a powerful
anabolichormone,mayberesponsiblefor
this decline, suggesting that early insulin
therapymaybebeneﬁcialinpatientswith
cysticﬁbrosisbeforetheonsetofCFRDas
currently deﬁned.
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